Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. [electronic resource]
Producer: 20170822Description: 523-533 p. digitalISSN:- 1533-4406
- Adult
- Aged
- Antineoplastic Agents -- adverse effects
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Genes, BRCA1
- Genes, BRCA2
- Germ-Line Mutation
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Phthalazines -- adverse effects
- Piperazines -- adverse effects
- Poly(ADP-ribose) Polymerase Inhibitors -- adverse effects
- Receptor, ErbB-2
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.